Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 10/2011

01-10-2011 | Short communication

The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure

Authors: Romina Molinari, Donatella D’Eliseo, Laura Manzi, Lello Zolla, Francesca Velotti, Nicolò Merendino

Published in: Cancer Immunology, Immunotherapy | Issue 10/2011

Login to get access

Abstract

Some anticancer chemotherapeutics, such as anthracyclines and oxaliplatin, elicit immunogenic apoptosis, meaning that dying cancer cells are engulfed by dendritic cells and tumor antigens are efficiently presented to CD8+ T cells, which control residual tumor cells. Immunogenic apoptosis is characterized by pre-apoptotic cell surface exposure of calreticulin (CRT), which usually resides into the endoplasmic reticulum. We investigated the ability of the n3-polyunsaturated fatty acid docosahexaenoic acid (22:6n3, DHA) to induce pre-apoptotic CRT exposure on the surface of the human PaCa-44 pancreatic and EJ bladder cancer cell lines. Cells were treated with 150 μM DHA for different time periods, and, by immunoblot and immunofluorescence, we showed that DHA induced CRT exposure, before the apoptosis-associated phosphatidylserine exposure. As for the known immunogenic compounds, CRT exposure was inhibited by the antioxidant GSH, the pan-caspase zVAD-FMK, and caspase-8 IETD-FMK inhibitor. We provide the first evidence that DHA induces CRT exposure, representing thus a novel potential anticancer immunogenic chemotherapeutic agent.
Literature
1.
go back to reference Lake RA, Robinson WS (2005) Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRef Lake RA, Robinson WS (2005) Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRef
2.
go back to reference Haynes NM, van der Most RG, Lake RA, Smyth MJ (2008) Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 20:545–571PubMedCrossRef Haynes NM, van der Most RG, Lake RA, Smyth MJ (2008) Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 20:545–571PubMedCrossRef
3.
go back to reference Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998PubMedCrossRef Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998PubMedCrossRef
4.
go back to reference Zitvogel L, Kepp O, Senovilla L et al (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16:3100–3104PubMedCrossRef Zitvogel L, Kepp O, Senovilla L et al (2010) Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 16:3100–3104PubMedCrossRef
5.
go back to reference Casares N, Pequignot MO, Tesniere A et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701PubMedCrossRef Casares N, Pequignot MO, Tesniere A et al (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202:1691–1701PubMedCrossRef
6.
go back to reference Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61PubMedCrossRef Obeid M, Tesniere A, Ghiringhelli F et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13:54–61PubMedCrossRef
7.
go back to reference Panaretakis T, Kepp O, Brockmeier U et al (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28:578–590PubMedCrossRef Panaretakis T, Kepp O, Brockmeier U et al (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28:578–590PubMedCrossRef
8.
go back to reference Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79:935–945PubMed Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79:935–945PubMed
9.
go back to reference Colas S, Paon L, Denis F et al (2004) Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int J Cancer 109:449–454PubMedCrossRef Colas S, Paon L, Denis F et al (2004) Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int J Cancer 109:449–454PubMedCrossRef
10.
go back to reference Bougnoux P, Hajjaji N, Ferrasson MN et al (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101:1978–1985PubMedCrossRef Bougnoux P, Hajjaji N, Ferrasson MN et al (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101:1978–1985PubMedCrossRef
11.
go back to reference Bradley MO, Webb NL, Anthony FH et al (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229–3238PubMed Bradley MO, Webb NL, Anthony FH et al (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7:3229–3238PubMed
12.
go back to reference El-Mesery M, Al-Gayyar M, Salem H et al (2009) Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div 4:6–23PubMed El-Mesery M, Al-Gayyar M, Salem H et al (2009) Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div 4:6–23PubMed
13.
go back to reference Serini S, Piccioni E, Merendino N, Calviello G (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14:135–152PubMedCrossRef Serini S, Piccioni E, Merendino N, Calviello G (2009) Dietary polyunsaturated fatty acids as inducers of apoptosis: implications for cancer. Apoptosis 14:135–152PubMedCrossRef
14.
go back to reference Merendino N, Molinari R, Loppi B, Pessina G, D’ Aquino M, Tomassi G, Velotti F (2003) Induction of apoptosis in human pancreatic cancer cells by docosahexaenoic acid. Ann NY Acad Sci 1010:361–364PubMedCrossRef Merendino N, Molinari R, Loppi B, Pessina G, D’ Aquino M, Tomassi G, Velotti F (2003) Induction of apoptosis in human pancreatic cancer cells by docosahexaenoic acid. Ann NY Acad Sci 1010:361–364PubMedCrossRef
15.
go back to reference Merendino N, Loppi B, D’Aquino M, Molinari R, Pessina G, Romano C, Velotti F (2005) Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active reduced glutathione extrusion and lipid peroxidation. Nutr Cancer 52:225–233PubMedCrossRef Merendino N, Loppi B, D’Aquino M, Molinari R, Pessina G, Romano C, Velotti F (2005) Docosahexaenoic acid induces apoptosis in the human PaCa-44 pancreatic cancer cell line by active reduced glutathione extrusion and lipid peroxidation. Nutr Cancer 52:225–233PubMedCrossRef
16.
go back to reference Kang KS, Wang P, Yamabe N et al (2010) Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase-8 activation. PLoS One 5:e10296PubMedCrossRef Kang KS, Wang P, Yamabe N et al (2010) Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase-8 activation. PLoS One 5:e10296PubMedCrossRef
Metadata
Title
The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure
Authors
Romina Molinari
Donatella D’Eliseo
Laura Manzi
Lello Zolla
Francesca Velotti
Nicolò Merendino
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 10/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1074-7

Other articles of this Issue 10/2011

Cancer Immunology, Immunotherapy 10/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine